Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

13 Jun 2011

GE and Mayo Clinic receive $5.7 million NIH grant to study dedicated MRI brain scanner technology

Driving new technologies that will help expand the availability of MRI scanners beyond the hospital to smaller clinic settings, GE Global Research, the technology development arm for the General Electric Company, and Mayo Clinic, have received a five-year, $5.7 million grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the National Institute of Neurological Disorders and Stroke (NINDS), components of the National Institutes of Health.

10 Jun 2011

Older people who engage in moderate to intense exercise less likely to have silent strokes

Older people who regularly exercise at a moderate to intense level may be less likely to develop the small brain lesions, sometimes referred to as "silent strokes," that are the first sign of cerebrovascular disease, according to a new study published in the June 8, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011

Scientists find neuronal cells die in Alzheimer's disease

In what they are calling a new direction in the study of Alzheimer's disease, UC Santa Barbara scientists have made an important finding about what happens to brain cells that are destroyed in Alzheimer's disease and related dementias.

8 Jun 2011

McGill researcher develops speedier technique for predicting protein folding pathways

Protein folding has nothing to do with laundry. It is, in fact, one of the central questions in biochemistry. Protein folding is the continual and universal process whereby the long, coiled strings of amino acids that make up proteins in all living things fold into more complex three-dimensional structures.

8 Jun 2011

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.

8 Jun 2011

FDA approves Mylan's ANDA for Donepezil HCl Tablets to treat dementia linked with Alzheimer's

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease.

8 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Study finds consistent link between Parkinson's disease and melanoma

An analysis of several studies shows that people with Parkinson's disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases.

7 Jun 2011

Weight loss following bariatric surgery may reduce risk of Alzheimer's

Obesity is a risk factor for Alzheimer's disease, but weight loss due to bariatric surgery may reduce the risk of this common dementia, a new study suggests. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Compassionate release programs for prisoners need to be reformed: Research

The nation's system of freeing some terminally ill prisoners on grounds of compassionate release is so riddled with medical flaws and procedural barriers that many potentially medically eligible inmates are dying behind bars, say UCSF researchers in a new study.

4 Jun 2011

Research in progress for novel protein kinase inhibitors: GEN

Biotech scientists are working on novel protein kinase inhibitors that are targeting a host of conditions ranging from atherosclerosis to neurodegenerative diseases, reports Genetic Engineering & Biotechnology News.

4 Jun 2011

Medical researchers uncover a novel approach to treat Huntington's disease

Medical researchers may have uncovered a novel approach to treat an incurable and ultimately fatal neurodegenerative disease that affects hundreds of thousands of people.

3 Jun 2011

New slow-release compound protects against Huntington's and Alzheimer's

A study in a special early online publication of Cell, a Cell Press publication, reveals a promising new slow-release compound that protects mice against the neurodegenerative effects of both Huntington's and Alzheimer's disease.

3 Jun 2011

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application to market a generic version of Eisai's Alzheimer's treatment Aricept Tablets, 5 mg and 10 mg. Shipment of this product has commenced.

2 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

1 Jun 2011

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.

1 Jun 2011

Many patients receive an incorrect dementia diagnosis: Lund study

Many patients receive an incorrect dementia diagnosis. This is shown by a study carried out by neuropathology researchers in Lund, Sweden.

31 May 2011

Alzheimer's Disease News and Research

Further Reading

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

GE and Mayo Clinic receive $5.7 million NIH grant to study dedicated MRI brain scanner technology

Older people who engage in moderate to intense exercise less likely to have silent strokes

Article reports on bright future and enormous need for stem cell therapeutics

Scientists find neuronal cells die in Alzheimer's disease

McGill researcher develops speedier technique for predicting protein folding pathways

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

FDA approves Mylan's ANDA for Donepezil HCl Tablets to treat dementia linked with Alzheimer's

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Study finds consistent link between Parkinson's disease and melanoma

Weight loss following bariatric surgery may reduce risk of Alzheimer's

Compassionate release programs for prisoners need to be reformed: Research

Research in progress for novel protein kinase inhibitors: GEN

Medical researchers uncover a novel approach to treat Huntington's disease

New slow-release compound protects against Huntington's and Alzheimer's

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

Many patients receive an incorrect dementia diagnosis: Lund study

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News